At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
MayFirst in the world to develop heart progenitor cells, giving new hope for testing drugs and treating heart failure patients. (Dr. Gordon Keller)
JanuaryGenerated polyhormonal cells that were insulin producing. (Dr. Gordon Keller)
AugustIdentify new approaches to mature liver cells to stage of efficient drug metabolization. (Dr. Gordon Keller)
NovemberIsolate pure population of cardiomyocytes and identifies epicardium and endocardium. (Dr. Gordon Keller)
FebruaryDiscover a pre-leukemic stem cell that may be the first step in initiating disease and also the culprit that evades therapy and triggers relapse in patients with acute myeloid leukemia (AML). (Dr. John Dick)
MayDevelop human cartilage tissue from human stem cells. (Dr. Gordon Keller)
AugustDemonstrate a new method to produce cholangiocytes (bile duct cells) from human pluripotent stem cells by providing the stem cells with certain activators at specific times during the production process. (Dr. Gordon Keller and Dr. Shinichiro Ogawa)
December 12McEwen Centre for Regenerative Medicine receives backing from BlueRock Therapeutics. Work of UHN scientists among first projects for new stem-cell research company to commercialize an approach to regenerating heart muscle in patients who have had a heart attack or suffer from chronic heart failure.
December 14Develop the first functional pacemaker cells from human stem cells, paving the way for alternate, biological pacemaker therapy. (Dr. Gordon Keller and Dr. Stephanie Protze)
August 24Develop a new method to identify and purify cells that develop into insulin-producing cells from human stem cells, creating opportunities for new therapies and safer transplants in patients with type 1 diabetes. (Dr. Maria Cristina Nostro)
December 6McEwen Stem Cell Institute is established.
August 8Bayer announces USD $1 billion acquisition of BlueRock Therapeutics, a company scientifically co-founded by Drs. Gordon Keller and Michael Laflamme.
November 6Dr. Gordon Keller receives top award — 2019 Ogawa-Yamanaka Stem Cell Prize—for his work in differentiating stem cells into multiple cell types.
July 7Pioneer the generation of functional liver blood vessel cells from stem cells, enabling the development of new therapies for disorders such as hemophilia A. (Dr. Gordon Keller)
September 25Develop first optical map of electric activity from engrafted stem cell-derived heart cells provides key insights on electric function. (Dr. Michael Laflamme)
October 11Dr. Cristina Nostro receives Business Excellence Award for Innovation and Science from the Italian Chamber of Commerce Canada. new therapies for valve diseases.
October 27Identify key signalling molecule responsible for generating endocardial cells, which line the inside of the heart, paving the way for new therapies for valve diseases (Dr. Gordon Keller)
November 25Dr. Gordon Keller received Bloom Burton Award for his work as the scientific co-founder of BlueRock Therapeutics.
November 27Dr. Cristina Nostro receives 1 of 2 national CIHR-JDRF grants totalling $3M to develop stem cell-based therapies for Type 1 Diabetes. She leads an expert team of scientists across Canada with expertise in stem cell biology, vascular biology, islet transplantation and beta cell biology.
December 16Drs. Gordon Keller and Michael Laflamme receive UHN Local Impact Award for Commercialization in recognition of their pioneering work that led to the creation of BlueRock Therapeutics.
May 26Dr. Gordon Keller develops a scalable protocol to develop heart muscle from human pluripotent stem cells. These cells have adult-like features, and can be used for disease modelling and treatment.
June 2Dr. Gordon Keller named co-recipient of 2021 Scientific Grand Prize from the Lefoulon Delalande Foundation at the Institute de France.
June 15Dr. Michael Laflamme appointed Tier 1 Canada Research Chair in Cardiovascular Regenerative Medicine
September 3Dr. Cristina Nostro and Dr. Sara Vasconcelos show that microvessels can increase the survival and functionality of transplanted pancreatic cells
November 15Dr. Shinichiro Ogawa uses pluripotent stem cells to generate cholangiocytes, which can be used to restore bile function in patients with biliary disease.
December 20Dr. Gordon Keller identifies pluripotent stem cell-derived blood cell precursor that gives rise to multiple blood lineages.
January 28Dr. Michael Laflamme develops new technique to generate mature heart cells that confer improved outcomes in laboratory models of heart disease.
March 31Dr. Cristina Nostro develops new method to improve safety of cell therapy for Type 1 Diabetes to mark 100 years since insulin was first used in clinic.
April 5Dr. Gordon Keller demonstrates reversal of hemophilia A with proof-of-concept cell therapy in laboratory model.
